ABOUT US

Founded in 2018, Taproot Health has pioneered and innovative new clinical trial: The Registry of Oncology
Outcomes Associated with Testing and Treatment (ROOT). Through this novel clinical trial, high-quality,
real-world data is collected and made available to researchers, laboratories, academic centers, and other
stakeholders to expedite drug discovery, personalize treatments, and advance cancer research.

OUR TEAM

Taproot Health’s focus is on the collection of regulatory-grade data. We have spent five years assembling an
Interdisciplinary team who understands the needs of clinicians, researchers, payers, and regulators. We have
Built a robust data collection platform and unique revenue-sharing model to make it possible.

DANE DICKSON, MD

CEO and Founder

Dr. Dickson is a medical oncologist with deep experience in clinical trial reporting, molecular medicine, and data collection.

MICK SIMON

President and Chief Technology Officer

Mick is President and acting Chief Technology Officer, guiding the operational and technology development of the Taproot Platform.

MITCH GALLOWAY

Chief Strategy Officer

Mr. Galloway has spent over 40 years in the healthcare sector as a hospital operator, consultant, and a serial entrepreneur.

GUY FORDHAM

Senior Vice President of Finance

Guy is a seasoned leader in all aspects of healthcare information technology finance.

LORI MILES

Director of Clinical Operations

Lori is an experienced program manager with over 11 years of experience in clinical trial work.

Renee Ubico

Clinical Site Manager

Renee is an expert in building relationships between medical providers, patients, and research teams to improve health outcomes.

RAZELLE KURZROCK, M.D.

Principal Investigator and Scientific Advisor

Chief, Division of Hematology & Oncology | Director, Center for Personalized Cancer Therapy & Clinical Trials Office | Senior Deputy Director, Clinical Science | Moores Cancer Center, University of California at San Diego.

RAYMOND BERGAN, M.D.

Principal Investigator and Scientific Advisor

Chief, Division of Hematology & Medical Oncology, Associate Director, Knight Cancer Institute.

JENNIFER JOHNSON, M.D., PHD

Principal Investigator and Scientific Advisor

Assistant Professor, Department of Medical Oncology, Thomas Jefferson

VIVEK SUBBIAH, M.D.

Principal Investigator and Scientific Advisor

Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.